Sandoz Shakes Up US Albuterol Market With Proventil Deal
In-Licenses Brand And Authorized Generic From Kindeva Drug Delivery
Executive Summary
Sandoz has struck a US deal to in-license both branded Proventil HFA and an authorized generic version of the albuterol sulfate product from Kindeva Drug Delivery. The deal comes after a busy year for generic versions of albuterol that have transformed the market dynamics for the respiratory treatment.
You may also be interested in...
Sandoz Bolsters Respiratory Aspirations With Coalesce Acquisition
Sandoz is targeting growth opportunities in the respiratory complex generics space with the acquisition of UK-based drug delivery device firm Coalesce.
Cipla Lines Up A Slate Of US Launches For FY23
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
Big US Launch Promise For Cipla In FY23, Eyes On Peptide Filings
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.